These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34118395)

  • 61. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
    Bejanin A; Schonhaut DR; La Joie R; Kramer JH; Baker SL; Sosa N; Ayakta N; Cantwell A; Janabi M; Lauriola M; O'Neil JP; Gorno-Tempini ML; Miller ZA; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2017 Dec; 140(12):3286-3300. PubMed ID: 29053874
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Sensitivity-Specificity of Tau and Amyloid β Positron Emission Tomography in Frontotemporal Lobar Degeneration.
    Ghirelli A; Tosakulwong N; Weigand SD; Clark HM; Ali F; Botha H; Duffy JR; Utianski RL; Buciuc M; Murray ME; Labuzan SA; Spychalla AJ; Pham NTT; Schwarz CG; Senjem ML; Machulda MM; Baker M; Rademakers R; Filippi M; Jack CR; Lowe VJ; Parisi JE; Dickson DW; Josephs KA; Whitwell JL
    Ann Neurol; 2020 Nov; 88(5):1009-1022. PubMed ID: 32869362
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Could tau-PET imaging contribute to a better understanding of the different patterns of clinical progression in Alzheimer's disease? A 2-year longitudinal study.
    Lagarde J; Olivieri P; Tonietto M; Rodrigo S; Gervais P; Caillé F; Moussion M; Bottlaender M; Sarazin M
    Alzheimers Res Ther; 2023 May; 15(1):91. PubMed ID: 37138309
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Intermediate flortaucipir uptake is associated with Aβ-PET and CSF tau in asymptomatic adults.
    McSweeney M; Pichet Binette A; Meyer PF; Gonneaud J; Bedetti C; Ozlen H; Labonté A; Rosa-Neto P; Breitner J; Poirier J; Villeneuve S;
    Neurology; 2020 Mar; 94(11):e1190-e1200. PubMed ID: 32015176
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Differences in gray and white matter
    Son HJ; Oh JS; Roh JH; Seo SW; Oh M; Lee SJ; Oh SJ; Kim JS
    Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):357-366. PubMed ID: 30109402
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Quantitative evaluation of tau PET tracers
    Chen J; Li Y; Pirraglia E; Okamura N; Rusinek H; de Leon MJ;
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1596-1604. PubMed ID: 29704038
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Predicting future rates of tau accumulation on PET.
    Jack CR; Wiste HJ; Weigand SD; Therneau TM; Lowe VJ; Knopman DS; Botha H; Graff-Radford J; Jones DT; Ferman TJ; Boeve BF; Kantarci K; Vemuri P; Mielke MM; Whitwell J; Josephs K; Schwarz CG; Senjem ML; Gunter JL; Petersen RC
    Brain; 2020 Oct; 143(10):3136-3150. PubMed ID: 33094327
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Kinetic Modeling of the Tau PET Tracer
    Barret O; Alagille D; Sanabria S; Comley RA; Weimer RM; Borroni E; Mintun M; Seneca N; Papin C; Morley T; Marek K; Seibyl JP; Tamagnan GD; Jennings D
    J Nucl Med; 2017 Jul; 58(7):1124-1131. PubMed ID: 27908967
    [No Abstract]   [Full Text] [Related]  

  • 70.
    Schonhaut DR; McMillan CT; Spina S; Dickerson BC; Siderowf A; Devous MD; Tsai R; Winer J; Russell DS; Litvan I; Roberson ED; Seeley WW; Grinberg LT; Kramer JH; Miller BL; Pressman P; Nasrallah I; Baker SL; Gomperts SN; Johnson KA; Grossman M; Jagust WJ; Boxer AL; Rabinovici GD
    Ann Neurol; 2017 Oct; 82(4):622-634. PubMed ID: 28980714
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
    Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A multicenter comparison of [
    Leuzy A; Pascoal TA; Strandberg O; Insel P; Smith R; Mattsson-Carlgren N; Benedet AL; Cho H; Lyoo CH; La Joie R; Rabinovici GD; Ossenkoppele R; Rosa-Neto P; Hansson O
    Eur J Nucl Med Mol Imaging; 2021 Jul; 48(7):2295-2305. PubMed ID: 34041562
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A comparison of visual assessment and semi-quantification for the diagnostic and prognostic use of [
    Mathoux G; Boccalini C; Peretti DE; Arnone A; Ribaldi F; Scheffler M; Frisoni GB; Garibotto V
    Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1639-1650. PubMed ID: 38182839
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pharmacokinetic Evaluation of the Tau PET Radiotracer
    Wooten DW; Guehl NJ; Verwer EE; Shoup TM; Yokell DL; Zubcevik N; Vasdev N; Zafonte RD; Johnson KA; El Fakhri G; Normandin MD
    J Nucl Med; 2017 Mar; 58(3):484-491. PubMed ID: 27660144
    [No Abstract]   [Full Text] [Related]  

  • 75. Sex differences in off-target binding using tau positron emission tomography.
    Smith R; Strandberg O; Leuzy A; Betthauser TJ; Johnson SC; Pereira JB; Hansson O
    Neuroimage Clin; 2021; 31():102708. PubMed ID: 34091353
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Reference Tissue-Based Kinetic Evaluation of 18F-AV-1451 for Tau Imaging.
    Baker SL; Lockhart SN; Price JC; He M; Huesman RH; Schonhaut D; Faria J; Rabinovici G; Jagust WJ
    J Nucl Med; 2017 Feb; 58(2):332-338. PubMed ID: 27587706
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults.
    Lowe VJ; Bruinsma TJ; Wiste HJ; Min HK; Weigand SD; Fang P; Senjem ML; Therneau TM; Boeve BF; Josephs KA; Pandey MK; Murray ME; Kantarci K; Jones DT; Vemuri P; Graff-Radford J; Schwarz CG; Machulda MM; Mielke MM; Roberts RO; Knopman DS; Petersen RC; Jack CR
    Neurology; 2019 Jul; 93(1):e29-e39. PubMed ID: 31147421
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Regional [
    Wolters EE; Ossenkoppele R; Verfaillie SCJ; Coomans EM; Timmers T; Visser D; Tuncel H; Golla SSV; Windhorst AD; Boellaard R; van der Flier WM; Teunissen CE; Scheltens P; van Berckel BNM
    Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2866-2878. PubMed ID: 32291510
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE.
    Schwarz CG; Senjem ML; Gunter JL; Tosakulwong N; Weigand SD; Kemp BJ; Spychalla AJ; Vemuri P; Petersen RC; Lowe VJ; Jack CR
    Neuroimage; 2017 Jan; 144(Pt A):113-127. PubMed ID: 27577718
    [TBL] [Abstract][Full Text] [Related]  

  • 80. PETPVE12: an SPM toolbox for Partial Volume Effects correction in brain PET - Application to amyloid imaging with AV45-PET.
    Gonzalez-Escamilla G; Lange C; Teipel S; Buchert R; Grothe MJ;
    Neuroimage; 2017 Feb; 147():669-677. PubMed ID: 28039094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.